Gabriel Pet Straps revenue explodes 475% after pharma acquisition
Standalone revenue surged to ₹177 crore in FY26. A new subsidiary bought 95% of Drug Centre's business in March, but its full impact is yet to be felt.
What's new
- Standalone revenue surged 475% to ₹177.23 crore; net profit rose to ₹3.71 crore.
- First consolidated results filed, showing ₹182.85 crore in revenue from new subsidiary Gabriel Ingrevia.
- Gabriel Ingrevia acquired 95% of Drug Centre's business in March 2026, after the reporting period.
Why this matters
The numbers confirm a fundamental reset for a nano-cap pet-strap maker. The consolidated filing, enabled by a new subsidiary, reveals a pharma distribution business is now the dominant revenue driver.
What we're watching
- First full-year operational performance of the Drug Centre business in FY27.
- How the thinning profit margins evolve as the new business scales.
- Any further capital raises to fund the expanded operations.
The full read
Gabriel Pet Straps posted standalone revenue of ₹177.23 crore for FY26. That's up nearly 5x from ₹30.84 crore. Net profit grew to ₹3.71 crore from ₹1.56 crore, but the margin clearly thinned. The real shift is in the first-ever consolidated numbers: ₹182.85 crore in revenue. That comes from Gabriel Ingrevia, a subsidiary set up in April 2025. Ingrevia bought 95% of Drug Centre's business in March. The deal closed after the year ended. Its full operational impact is yet to be felt. For a ₹98 crore market-cap firm, this is a fundamental reset.
Questions answered
- What drove the 475% revenue increase?
- The standalone revenue growth to ₹177.23 crore is the audited annual result. The higher consolidated figure of ₹182.85 crore includes Gabriel Ingrevia, the subsidiary that bought 95% of Drug Centre's business.
- Did profits grow as fast as revenue?
- No. Net profit rose to ₹3.71 crore from ₹1.56 crore, a 138% increase. This is far slower than the 475% revenue growth, indicating the new business or scaling costs compressed margins.
- When does the Drug Centre acquisition start contributing fully?
- The deal closed on March 20, 2026, just 11 days before the financial year ended. Its operations commenced after the reporting period, so its full impact will be seen in the FY27 consolidated results.
- Is the core pet-strap business growing?
- The filing does not break out the legacy pet-strap revenue from the new pharmaceutical distribution revenue. The conglomerated numbers mask the performance of the original business.